Small Cap Feast

Small Cap Feast – 22 July 2020

Dish of the Day:

No Joiners Today


Off the Menu:

No Leavers Today


What’s Cooking in the IPO Kitchen?

AEX Gold (TSXV:AEV) is intending to admit its shares to AIM alongside a £45m placing. The Company, led by CEO Eldur Ólafsson, has established the largest land package of gold assets in Greenland with a current portfolio of licences covering 3,356 square kilometres, in the two known gold belts in Southern Greenland, the Nanortalik and Tartoq gold belts. Nalunaq is a high-grade gold asset with an updated Inferred Mineral Resource covering 422,770 tonnes at 18.5 grams per tonne of gold, or 250,970 ounces of gold, which covers the area in and around the historical mine.  Due July.  Current mkt cap C$66.7m.


Breakfast Buffet

Altus Strategies 59.5p £41.7m (ALS.L)

Positive results from a Preliminary Economic Assessment (“PEA”) for its 100% owned Diba gold project in western Mali .

  • Positive PEA for an open-pit oxide gold mine with strong cashflow and rapid payback
  • Project economics applying a 10% discount rate and US$1,500/oz gold price: o  Pre-tax NPV of US$115 million, IRR of 728% and payback of 6.2 months; o  After-tax NPV of US$81 million, IRR of 469% and payback of 6.9 months
  • Project economics applying a 5% discount rate and US$1,800/oz gold price:
  • Average production of 52,000oz per year with 3.25 year mine life and low strip ratio of 1:1.37
  • Significant growth potential for Diba project: o  Seven further significant oxide gold targets to be systemically drill tested

o  Metallurgical study to test potential for sulphide ores to be processed via CIL · Diba is contiguous with the Sadiola mining permit at the heart of a world renowned belt


Tristel 410p £185.7 m (TSTL.L)

The manufacturer of infection prevention products, provides a trading update for the year ended 30 June 2020.

The Company confirms that results will be ahead of market expectations and expects to report turnover of no less than £31.6m (2019: £26.2m), a 21% increase, and adjusted pre-tax profit (before share-based payments) of at least £6.8m (2019: £5.6m), a 21% increase. Revenues from overseas markets increased by 32% and contributed 60% of total revenues – a record level (2019: 55%). Revenue in the UK, the Company’s largest and most mature market, rose by 7%. 


Itaconix 1.35p £5.84m (ITX.L)

The innovator in sustainable specialty polymers , put out a trading update for the half year to 30 June 2020.

Further to previous updates, the Company has continued to enjoy improved momentum with strong demand for its range of specialty polymers. Unaudited revenues for the first six months of the year were $1.1 million, representing circa 80% growth over the equivalent period in 2019 and circa 62% over the second half of 2019. As a result of the increase in revenues, unaudited LBITDA has decreased in line with management’s expectations. 

Volumes and revenues increased from new and recurring orders in detergent, odour control, and personal care applications. Significant revenue growth has come from customers successfully launching new dishwashing products using Itaconix formulas based on the Company’s new TSI 322 detergent polymer. In addition, several existing customers have increased the size of their recurring orders during the year partly to satisfy increased consumer buying related to stay-at-home practices in response to Covid-19.  The Company has increased production rates to keep up with anticipated demand across an increasingly diverse customer base.


Eve Sleep 2.125p £5.8m (EVE.L)

The direct to consumer sleep wellness brand operating in the UK, Ireland (together the UK&I) and France announces a trading update for the six months ended 30 June .  the direct to consumer sleep wellness brand operating in the UK, Ireland (together the UK&I) and France announces a trading update for the six months ended 30 June . Group revenue of £12.2 million – ahead of the Board’s expectations following strong trading in May and June

Positive marketing contribution for the period.

Underlying H1 EBITDA loss reduced year-on-year by c.80% to approximately £1.2 million – ahead of the Board’s expectations

Cash flow positive in the period

Net cash at 30 June 2020 of £9.1m (31 December 2019: £8.0m)

“We are well placed to benefit from the accelerated shift to online ordering and the increase in spend on homewares as consumers increase investment in their homes. eve will continue to focus on driving value for our shareholders and building a sustainably profitable business with strong growth potential.”


Scancell 7.25p £33.74m (SCLP.L)

The developer of novel immunotherapies for the treatment of cancer, today announces a proposed conditional Capital Raise to raise in aggregate up to approximately £15 million before expenses, with equity priced at 5.5p and £6m convertible notes with a conversion price of 6.2p.

The net proceeds from the Capital Raise, in addition to the Company’s existing cash resources and anticipated tax credits, will be used to:

  • strengthen the Company’s balance sheet to support potential partnering discussions for the Company’s antibody technology;
  • support clinical trials for Modi-1 Phase 1/2 and SCIB1 Phase 2; and
  • continue initial COVID-19 vaccine development until non-dilutive funding or third-party partnering transaction.


GYG 81p £37.8m (GYG.L)

The market leading superyacht painting, maintenance and supply company, today announces its audited Final Results for the year ended 31 December 2019.

Financial Highlights

  • Group revenue increased 41.8% to EUR63.8m (FY18: EUR45.0m)
  • Profit before tax increased to EUR0.8m (FY18: loss of EUR4.6m)
  • Net debt position2 of EUR8.2m at 31 December 2019 (FY18: EUR7.8m )
  • Cash of EUR5.5m at 31 December 2019 (EUR5.1m at 31 December 2018)

Orderbook EUR42.7m from EUR38.6m


Tekcapital 10p £8.8m (TEK.L)

The UK intellectual property (IP) investment group focused on creating marketplace value from investing in university technology, announced that its wholly owned portfolio company Lucyd Ltd, (“Lucyd”) the smartglass developer and operator of an eShop for tech-enhanced eyewear, has received a notice of allowance for 13 previously filed patents and has filed two new patents covering their forthcoming Lucyd Lyte Bluetooth® audio glasses.

 As a result,  Lucyd’s total IP position now consists of 24 patents (13 allowed design patents & 11 applications) which includes three pending utility patents,  and eight pending design patents.

 The Company’s manufacturing partner has just completed the first Lucyd Lyte beta production models, dubbed ” Darkside” and ‘Moonshot .” Lucyd expect to have the initial batch of the Lucyd Lyte beta units next week, and will begin beta testing with our network of tech and fashion influencers, and Lucyd eyewear fans. The Product launch for the Lyte line is anticipated to be in late September 2020.


Diaceutics 167.5p £141m (DXRX.L)

The diagnostic commercialisation company, announces a significant new client contract win with a leading pharmaceutical company. 

Diaceutics’ will collaborate with this new client to produce an outsourced commercial solution for its US market, using the Company’s new DXRX platform to improve patient testing and support the client’s pioneering activities in the field of immunotherapy. This initial contract is worth $1.27 million.


Blancco 187p £141m (BLTG.L)

The industry standard in data erasure and mobile device diagnostics, provides the following trading update for the financial year ended 30 June 2020 (“FY 2020”).

Blancco has continued to benefit from strong structural tailwinds which have supported continued revenue and profit growth in FY 2020. Although the COVID-19 pandemic lengthened sales cycles in the second half of FY 2020, the Board expect results for FY 2020 to be in line with current market expectations with revenue of approximately £33.4m (FY19: £30.5m) and Adjusted Operating Profit of approximately £4.0m (FY19: £3.5m). As anticipated at the time of the Group’s interim results in February 2020, cash generation has continued to improve in the second half of FY 2020 and the Group ended the year with £6.7m of net cash (30 June 2019: £0.1m).


Alba Mineral Resources 0.0825p £3.4m (ALBA.L)

Update on the Company’s field activities.

Key Points

Work activities at Clogau Gold Project have resumed following easing of COVID-19 lockdown.

The priority for Clogau for the remainder of 2020 will be the execution of an underground bulk sampling programme, subject to receipt of regulatory approvals.

The first bulk sample will be processed off-site at an accredited processing facility in the UK. Thereafter, Alba will establish its own dedicated pilot processing plant.

Amitsoq drilling programme deferred until 2021.


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.